Hypoplastic left heart syndrome: valuing the survival

Area of Science:

• Pediatric Cardiology
• Congenital Heart Surgery
• Developmental Pediatrics

Background:

• Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect requiring complex surgical palliation.
• Staged reconstructive surgery aims to improve survival and quality of life for affected children.

Purpose of the Study:

• To evaluate survival rates, developmental status, quality of life, and direct medical costs in children with HLHS undergoing staged surgical repair (Stages I, II, and III).

Main Methods:

• Kaplan-Meier survival analysis was performed on 106 children with HLHS who underwent staged repair between 1990 and 1999.
• Quality of life and developmental progress were assessed using validated parent-reported questionnaires (CHQ-PF28, ASQ).
• Hospital costs were calculated using the ratio-of-costs-to-charges method; physician and outpatient medication costs were also captured.

Main Results:

• Institutional 1- and 5-year survival rates were 58% and 54%, respectively. Predictors of survival included birth weight, need for inotropic drugs, and surgical experience.
• Children undergoing Norwood Stage I repair showed fewer developmental milestones compared to those surviving to later stages.
• Median inpatient costs for Stages I, II, and III were $51,000, $33,892, and $52,183, with outpatient/readmission costs <10% of total.

Conclusions:

• Staged surgical repair for HLHS yields moderate survival rates but highlights potential developmental challenges in early stages.
• Further prospective research is necessary to comprehensively assess long-term developmental and quality-of-life outcomes, alongside cost-effectiveness of staged palliation and heart transplantation.